What is the difference between Pralsetinib and Vemurafenib?

Pralsetinib and Vemurafenib are both Targeted Cancer Therapys, so they work through the same broad mechanism. They differ in dosing, half-life, side-effect frequency, and how individual patients tolerate them. See the head-to-head sections below for the specifics.

Can Pralsetinib and Vemurafenib be used for the same conditions?

Both medications are prescribed for overlapping indications including See full prescribing information. Always verify with your prescriber and the current FDA label before switching.

Is Gavreto the same as Zelboraf?

No. Gavreto (Pralsetinib) and Zelboraf (Vemurafenib) are distinct medications. They are sometimes confused because of similar branding or because they treat overlapping conditions, but they have different active ingredients and different safety profiles.

Which has fewer side effects, Pralsetinib or Vemurafenib?

Side-effect frequency varies by individual. The side-effect comparison section on this page shows FAERS-reported events for each drug side by side. FAERS is voluntary reporting, so it reflects what patients and clinicians chose to report, not absolute population risk.

Can I switch from Pralsetinib to Vemurafenib?

Switching medications should always be done under prescriber supervision. The "patient stories" section on this page includes accounts from people who have made the switch and what their transition felt like, but those are individual experiences, not protocols.

Pralsetinib vs Vemurafenib

Compare Pralsetinib (Gavreto) and Vemurafenib (Zelboraf), clinical data, side effects, and patient experiences.

Pralsetinib

Gavreto · Targeted Cancer Therapy

How it works

12.1 Mechanism of Action Pralsetinib is a kinase inhibitor of wild-type RET and oncogenic RET fusions (CCDC6- RET ) and mutations ( RET V804L, RET V804M and RET M918T) with half ma...

Approved for

See full prescribing information

OralTablet

Vemurafenib

Zelboraf · Targeted Cancer Therapy

How it works

12.1 Mechanism of Action Vemurafenib is a low molecular weight, orally available inhibitor of some mutated forms of BRAF serine- threonine kinase, including BRAF V600E. Vemurafenib...

Approved for

2.1 ) ZELBORAF ® is indicated for the treatment of patients with Erdheim- Chester Disease with BRAF V600 mutation. ( 1.2

2.1 ) Limitation of Use: ZELBORAF is not indicated for treatment of patients with wild-type BRAF melanoma ( 2.1

OralTablet

Quick Comparison

PralsetinibVemurafenib

Drug Class

Targeted Cancer Therapy

Route

Oral

Half-Life

N/A

FDA Approved

N/A

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

Pralsetinib

Fatigue

1-10%

Weakness

1-10%

Diarrhea

1-10%

High Blood Pressure

1-10%

Constipation

1-10%

Fever

1-10%

Vemurafenib

Rash

>10%

Joint Pain

1-10%

Fatigue

1-10%

Diarrhea

1-10%

Nausea

1-10%

Fever

1-10%

Hair Loss

0.1-1%

Decreased Appetite

0.1-1%

FDA Warnings

Pralsetinib

5 WARNINGS AND PRECAUTIONS Serious Infections, Including Opportunistic Infections: Monitor for signs and symptoms of infection and treat appropriately
5 ) Tumor Lysis Syndrome: Closely monitor patients at risk and treat as clinically indicated
6 ) Risk of Impaired Wound Healing: Withhold GAVRETO for at least 5 days prior to elective surgery
Advise females of reproductive potential of the potential risk to a fetus and to use effective non-hormonal contraception

Vemurafenib

5 WARNINGS AND PRECAUTIONS New Primary Cutaneous Malignancies: Perform dermatologic evaluations prior to initiation of therapy, every 2 months while on therapy, and for up to 6 months following discontinuation of ZELBORAF
Serious Hypersensitivity Reactions including anaphylaxis and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome): Discontinue ZELBORAF for severe hypersensitivity reactions
Correct electrolyte abnormalities and control for cardiac risk factors for QT prolongation
7 ) Serious Ophthalmologic Reactions: Monitor for signs and symptoms of uveitis

Clinical Trial Data

No head-to-head clinical studies found for Pralsetinib vs Vemurafenib.

Pralsetinib vs Vemurafenib: What You Should Know

Key Differences

Both Pralsetinib and Vemurafenib belong to the Targeted Cancer Therapy class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients.

Safety Considerations

Pralsetinib carries 4 FDA warnings. Vemurafenib carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

Lorlatinib vs Pralsetinib→Pralsetinib vs Sorafenib→Gefitinib vs Pralsetinib→Larotrectinib vs Pralsetinib→Ibrutinib vs Pralsetinib→Brigatinib vs Pralsetinib→

Primary sources

Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.

Pralsetinib: DailyMed label · FAERS adverse events · ClinicalTrials.gov
Vemurafenib: DailyMed label · FAERS adverse events · ClinicalTrials.gov

Loading comparison data...

Pralsetinib vs Vemurafenib

Compare Pralsetinib (Gavreto) and Vemurafenib (Zelboraf), clinical data, side effects, and patient experiences.

Pralsetinib

Gavreto · Targeted Cancer Therapy

How it works

12.1 Mechanism of Action Pralsetinib is a kinase inhibitor of wild-type RET and oncogenic RET fusions (CCDC6- RET ) and mutations ( RET V804L, RET V804M and RET M918T) with half ma...

Approved for

See full prescribing information

OralTablet

Vemurafenib

Zelboraf · Targeted Cancer Therapy

How it works

12.1 Mechanism of Action Vemurafenib is a low molecular weight, orally available inhibitor of some mutated forms of BRAF serine- threonine kinase, including BRAF V600E. Vemurafenib...

Approved for

2.1 ) ZELBORAF ® is indicated for the treatment of patients with Erdheim- Chester Disease with BRAF V600 mutation. ( 1.2

2.1 ) Limitation of Use: ZELBORAF is not indicated for treatment of patients with wild-type BRAF melanoma ( 2.1

OralTablet

Quick Comparison

PralsetinibVemurafenib

Drug Class

Targeted Cancer Therapy

Route

Oral

Half-Life

N/A

FDA Approved

N/A

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

Pralsetinib

Fatigue

1-10%

Weakness

1-10%

Diarrhea

1-10%

High Blood Pressure

1-10%

Constipation

1-10%

Fever

1-10%

Vemurafenib

Rash

>10%

Joint Pain

1-10%

Fatigue

1-10%

Diarrhea

1-10%

Nausea

1-10%

Fever

1-10%

Hair Loss

0.1-1%

Decreased Appetite

0.1-1%

FDA Warnings

Pralsetinib

5 WARNINGS AND PRECAUTIONS Serious Infections, Including Opportunistic Infections: Monitor for signs and symptoms of infection and treat appropriately
5 ) Tumor Lysis Syndrome: Closely monitor patients at risk and treat as clinically indicated
6 ) Risk of Impaired Wound Healing: Withhold GAVRETO for at least 5 days prior to elective surgery
Advise females of reproductive potential of the potential risk to a fetus and to use effective non-hormonal contraception

Vemurafenib

5 WARNINGS AND PRECAUTIONS New Primary Cutaneous Malignancies: Perform dermatologic evaluations prior to initiation of therapy, every 2 months while on therapy, and for up to 6 months following discontinuation of ZELBORAF
Serious Hypersensitivity Reactions including anaphylaxis and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome): Discontinue ZELBORAF for severe hypersensitivity reactions
Correct electrolyte abnormalities and control for cardiac risk factors for QT prolongation
7 ) Serious Ophthalmologic Reactions: Monitor for signs and symptoms of uveitis

Clinical Trial Data

No head-to-head clinical studies found for Pralsetinib vs Vemurafenib.

Pralsetinib vs Vemurafenib: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.